• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.I 型干扰素信号通过降低抗原表达来阻止乙型肝炎病毒特异性 T 细胞应答。
J Virol. 2018 Nov 12;92(23). doi: 10.1128/JVI.01099-18. Print 2018 Dec 1.
2
Intrahepatic Cross-Presentation and Hepatocellular Antigen Presentation Play Distinct Roles in the Induction of Hepatitis B Virus-Specific CD8 T Cell Responses.肝内交叉呈递和肝细胞抗原呈递在诱导乙型肝炎病毒特异性 CD8 T 细胞应答中发挥不同作用。
J Virol. 2018 Oct 12;92(21). doi: 10.1128/JVI.00920-18. Print 2018 Nov 1.
3
Vaccination with ubiquitin-hepatitis B core antigen-cytoplasmic transduction peptide enhances the hepatitis B virus-specific cytotoxic T-lymphocyte immune response and inhibits hepatitis B virus replication in transgenic mice.用泛素-乙肝核心抗原-细胞质转导肽进行疫苗接种可增强转基因小鼠的乙肝病毒特异性细胞毒性T淋巴细胞免疫反应并抑制乙肝病毒复制。
Mol Med Rep. 2015 Sep;12(3):3591-3598. doi: 10.3892/mmr.2015.3834. Epub 2015 May 25.
4
Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.编码泛素化乙肝核心抗原的慢病毒载体在乙肝病毒转基因小鼠中诱导强大的细胞免疫反应和治疗性免疫。
Immunobiology. 2016 Jul;221(7):813-21. doi: 10.1016/j.imbio.2016.01.015. Epub 2016 Feb 2.
5
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.表达嵌合抗原受体的 T 细胞能结合乙型肝炎病毒包膜蛋白,从而控制小鼠体内病毒复制。
Gastroenterology. 2013 Aug;145(2):456-65. doi: 10.1053/j.gastro.2013.04.047. Epub 2013 Apr 30.
6
Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.用于慢性乙型肝炎病毒感染的基于病毒样囊泡的治疗性疫苗载体
J Virol. 2015 Oct;89(20):10407-15. doi: 10.1128/JVI.01184-15. Epub 2015 Aug 5.
7
Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance.治疗性恢复乙型肝炎病毒(HBV)诱导的肝细胞固有免疫缺陷可逆转全身适应性免疫耐受。
Hepatology. 2013 Jul;58(1):73-85. doi: 10.1002/hep.26339. Epub 2013 May 23.
8
Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8 T cell responses in naïve and persistently infected mice and protects from challenge.基于水泡病毒载体的异源初免-加强免疫方案,表达 HBV 核心抗原,可在未感染和持续性感染的小鼠中诱导 CD8 T 细胞应答,并能预防挑战感染。
Antiviral Res. 2019 Aug;168:156-167. doi: 10.1016/j.antiviral.2019.05.014. Epub 2019 May 30.
9
Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.HBV 感染过程中 CD8+T 细胞表位呈现的时空差异。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01457-18. Print 2019 Feb 15.
10
Kupffer Cells Support Hepatitis B Virus-Mediated CD8+ T Cell Exhaustion via Hepatitis B Core Antigen-TLR2 Interactions in Mice.库普弗细胞通过乙肝核心抗原与Toll样受体2的相互作用促进小鼠体内乙肝病毒介导的CD8 + T细胞耗竭
J Immunol. 2015 Oct 1;195(7):3100-9. doi: 10.4049/jimmunol.1500839. Epub 2015 Aug 24.

引用本文的文献

1
Intrahepatic Exhausted Antiviral Immunity in an Immunocompetent Mouse Model of Chronic Hepatitis B.慢性乙型肝炎免疫健全小鼠模型中的肝内抗病毒耗竭免疫
Cell Mol Gastroenterol Hepatol. 2025;19(1):101412. doi: 10.1016/j.jcmgh.2024.101412. Epub 2024 Sep 28.
2
HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis.HBV 感染与宿主相互作用:在病毒持续存在和致癌中的作用。
Int J Mol Sci. 2023 Apr 21;24(8):7651. doi: 10.3390/ijms24087651.
3
Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2.伊维菌素通过抑制 KPNA2 抑制 HBV 进入细胞核。
Viruses. 2022 Nov 8;14(11):2468. doi: 10.3390/v14112468.
4
Interferon and Hepatitis B: Current and Future Perspectives.干扰素与乙型肝炎:现状与未来展望。
Front Immunol. 2021 Sep 7;12:733364. doi: 10.3389/fimmu.2021.733364. eCollection 2021.
5
Simultaneous or Prior Activation of Intrahepatic Type I Interferon Signaling Leads to Hepatitis B Virus Persistence in a Mouse Model.肝内I型干扰素信号的同时激活或预先激活导致小鼠模型中的乙型肝炎病毒持续感染。
J Virol. 2021 Nov 23;95(24):e0003421. doi: 10.1128/JVI.00034-21. Epub 2021 Sep 22.
6
HBV-Specific CD8+ T-Cell Tolerance in the Liver.HBV 特异性 CD8+ T 细胞在肝脏中的耐受。
Front Immunol. 2021 Aug 6;12:721975. doi: 10.3389/fimmu.2021.721975. eCollection 2021.
7
An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells.一种从多能干细胞中生成乙型肝炎病毒病毒抗原特异性 T 淋巴细胞的优化方案。
STAR Protoc. 2021 Jan 12;2(1):100264. doi: 10.1016/j.xpro.2020.100264. eCollection 2021 Mar 19.
8
Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation.在肝内初始 CD8+T 细胞中恢复 I 型干扰素信号转导促进功能分化。
JCI Insight. 2021 Feb 8;6(3):145761. doi: 10.1172/jci.insight.145761.
9
Stem Cell-Derived Viral Antigen-Specific T Cells Suppress HBV Replication through Production of IFN-γ and TNF-⍺.干细胞衍生的病毒抗原特异性T细胞通过产生IFN-γ和TNF-α抑制乙肝病毒复制。
iScience. 2020 Jul 24;23(7):101333. doi: 10.1016/j.isci.2020.101333. Epub 2020 Jul 1.

本文引用的文献

1
HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.HBV 绕过先天免疫反应,不能保护 HCV 免受干扰素的抗病毒活性。
Gastroenterology. 2018 May;154(6):1791-1804.e22. doi: 10.1053/j.gastro.2018.01.044. Epub 2018 Feb 1.
2
Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver.乙型肝炎病毒不会干扰人体肝脏中的固有免疫反应。
Gastroenterology. 2018 May;154(6):1778-1790. doi: 10.1053/j.gastro.2018.01.034. Epub 2018 Mar 19.
3
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.慢性乙型肝炎的预防、诊断和治疗最新进展:美国肝病研究学会2018年乙型肝炎指南
Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.
4
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南:乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
5
Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models.在小鼠模型中,男性乙型肝炎病毒特异性 T 细胞反应较低与调节性 T 细胞数量较高相关。
Hepatology. 2017 Jul;66(1):69-83. doi: 10.1002/hep.29155. Epub 2017 May 26.
6
Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.阻断I型干扰素信号传导可增强T细胞恢复并减少HIV-1储存库。
J Clin Invest. 2017 Jan 3;127(1):269-279. doi: 10.1172/JCI90745. Epub 2016 Dec 12.
7
The Concept of Immune Tolerance in Chronic Hepatitis B Virus Infection Is Alive and Well.慢性乙型肝炎病毒感染中免疫耐受的概念依然存在且情况良好。
Gastroenterology. 2016 Nov;151(5):801-804. doi: 10.1053/j.gastro.2016.09.037. Epub 2016 Oct 1.
8
Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission.母体来源的乙肝病毒e抗原改变子代巨噬细胞功能以驱动垂直传播后的病毒持续感染。
Immunity. 2016 May 17;44(5):1204-14. doi: 10.1016/j.immuni.2016.04.008. Epub 2016 May 3.
9
Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.新型 pH 敏感多功能包膜型纳米装置,用于基于 siRNA 的慢性乙型肝炎病毒感染治疗。
J Hepatol. 2016 Mar;64(3):547-55. doi: 10.1016/j.jhep.2015.10.014. Epub 2015 Oct 24.
10
Regulation of antiviral T cell responses by type I interferons.I 型干扰素对抗病毒 T 细胞应答的调节作用。
Nat Rev Immunol. 2015 Apr;15(4):231-42. doi: 10.1038/nri3806. Epub 2015 Mar 20.

I 型干扰素信号通过降低抗原表达来阻止乙型肝炎病毒特异性 T 细胞应答。

Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.

机构信息

Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

J Virol. 2018 Nov 12;92(23). doi: 10.1128/JVI.01099-18. Print 2018 Dec 1.

DOI:10.1128/JVI.01099-18
PMID:30209178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6232490/
Abstract

Robust virus-specific CD8 T cell responses are required for the clearance of hepatitis B virus (HBV). However, the factors that determine the magnitude of HBV-specific CD8 T cell responses are poorly understood. To examine the impact of genetic variations of HBV on HBV-specific CD8 T cell responses, we introduced three HBV clones (Aa_IND [Aa], C_JPN22 [C22], and D_IND60 [D60]) that express various amounts of HBV antigens into the livers of C57BL/6 (B6) (H-2b) mice and B10.D2 (H-2d) mice. In B6 mice, clone C22 barely induced HBV-specific CD8 T cell responses and persisted the longest, while clone D60 elicited strong HBV-specific CD8 T cell responses and was rapidly cleared. These differences between HBV clones largely diminished in H-2d mice. Interestingly, the magnitude of HBV-specific CD8 T cell responses in B6 mice was associated with the HB core antigen expression level during the early phase of HBV transduction. Surprisingly, robust HBV-specific CD8 T cell responses to clone C22 were induced in interferon-α/β receptor-deficient (IFN-αβR) (H-2b) mice. The induction of HBV-specific CD8 T cell responses to C22 in IFN-αβR mice reflects enhanced HBV antigen expression because the suppression of antigen expression by HBV-specific small interfering RNA (siRNA) attenuated HBV-specific T cell responses in IFN-αβR mice and prolonged HBV expression. Collectively, these results suggest that HBV genetic variation and type I interferon signaling determine the magnitude of HBV-specific CD8 T cell responses by regulating the initial antigen expression levels. Hepatitis B virus (HBV) causes acute and chronic infection, and approximately 240 million people are chronically infected with HBV worldwide. It is generally believed that virus-specific CD8 T cell responses are required for the clearance of HBV. However, the relative contributions of genetic variation and innate immune responses to the induction of HBV-specific CD8 T cell responses are not fully understood. In this study, we discovered that different clearance rates between HBV clones after hydrodynamic transduction were associated with the magnitude of HBV-specific CD8 T cell responses and initial HB core antigen expression. Surprisingly, type I interferon signaling negatively regulated HBV-specific CD8 T cell responses by reducing early HBV antigen expression. These results show that the magnitude of the HBV-specific CD8 T cell response is regulated primarily by the initial antigen expression level.

摘要

为了清除乙型肝炎病毒 (HBV),需要产生强大的病毒特异性 CD8 T 细胞反应。然而,决定 HBV 特异性 CD8 T 细胞反应大小的因素还了解甚少。为了研究 HBV 遗传变异对 HBV 特异性 CD8 T 细胞反应的影响,我们将三种表达不同 HBV 抗原量的 HBV 克隆(Aa_IND [Aa]、C_JPN22 [C22]和 D_IND60 [D60])引入 C57BL/6(B6)(H-2b)小鼠和 B10.D2(H-2d)小鼠的肝脏中。在 B6 小鼠中,C22 克隆几乎不能诱导 HBV 特异性 CD8 T 细胞反应,而且持续时间最长,而 D60 克隆则能诱导强烈的 HBV 特异性 CD8 T 细胞反应,并迅速被清除。这些 HBV 克隆之间的差异在 H-2d 小鼠中大大减少。有趣的是,B6 小鼠中 HBV 特异性 CD8 T 细胞反应的大小与 HBV 转导早期 HB 核心抗原的表达水平有关。令人惊讶的是,在干扰素-α/β受体缺陷(IFN-αβR)(H-2b)小鼠中,能够诱导对 C22 克隆的强烈 HBV 特异性 CD8 T 细胞反应。IFN-αβR 小鼠中 C22 克隆诱导的 HBV 特异性 CD8 T 细胞反应反映了 HBV 抗原表达的增强,因为 HBV 特异性小干扰 RNA(siRNA)抑制抗原表达会减弱 IFN-αβR 小鼠中的 HBV 特异性 T 细胞反应并延长 HBV 的表达。总的来说,这些结果表明,HBV 遗传变异和 I 型干扰素信号通过调节初始抗原表达水平来决定 HBV 特异性 CD8 T 细胞反应的大小。乙型肝炎病毒 (HBV) 可引起急性和慢性感染,全世界约有 2.4 亿人慢性感染 HBV。人们普遍认为,病毒特异性 CD8 T 细胞反应是清除 HBV 所必需的。然而,HBV 特异性 CD8 T 细胞反应的诱导与遗传变异和先天免疫反应的相对贡献尚不完全清楚。在这项研究中,我们发现,水力转导后不同 HBV 克隆的清除率与 HBV 特异性 CD8 T 细胞反应的大小和初始 HB 核心抗原的表达有关。令人惊讶的是,I 型干扰素信号通过减少早期 HBV 抗原表达来负调控 HBV 特异性 CD8 T 细胞反应。这些结果表明,HBV 特异性 CD8 T 细胞反应的大小主要受初始抗原表达水平的调节。